If someone wanted to use a Venn diagram to illustrate what is wrong with the U.S. health care system, picking the different sets would be easy: Price gouging, abuse of loopholes, hidden risks to patients, baffling regulatory decisions, marginal efficacies and the use of doctor payments to stimulate drug sales would be some logical choices.
Pharma
Mr. Schiller’s $9 Million Worth of Reasons to Work Cheaply
|
Valeant Pharmaceuticals is the type of company that tends to make even the simplest things complex.
Pharma
The Brotherhood of Thieves: Insys Therapeutics
|
Executives at Insys Therapeutics have continued to pressure its employees to develop new ways to mislead insurance companies into granting coverage to patients prescribed its drug Subsys, even as the Food and Drug Administration’s Office of Criminal Investigations is issuing a stream of subpoenas to former employees.
Pharma
Murder Incorporated: Insys Therapeutics, Part II
|
The Insys that investors loved and that made its founder and chairman John Kapoor a billionaire is going away and, despite heroic efforts by company officials to rebrand it as a research and development-driven shop, its future will probably be less profitable, with little of the mercurial growth and compounding profits that defined its first four years.
Pharma
Murder Incorporated: Insys Therapeutics, Part I
|
Insys Therapeutics is a company in a great deal of trouble. Starting late last year critical press reports detailed alleged business practices at Insys so aggressive as to make the company an outlier in the oft-sanctioned pharmaceutical industry.
Pharma
Valeant’s Eastern Front
|
Poland seems a most unlikely place for the next chapter of Valeant Pharmaceuticals’ saga to play out. Weighing in at about 3 percent of sales, the Polish operations are seemingly a modest contributor to Valeant’s fast growing bottom line.
Pharma
The Curious Case of Mr. Pearson’s 502,996 Shares
|
On Valeant Pharmaceuticals’ conference call on Nov. 10, embattled chief executive J. Michael Pearson offered several defenses of his company’s internal controls and procedures.
Pharma
The Pawn Isolated: Valeant, Philidor and the Annals of Fraud
|
The Southern Investigative Reporting Foundation’s story looking at Valeant Pharmaceuticals’ well-concealed relationship with Philidor Rx Services, struck a nerve.
Pharma
The King’s Gambit: Valeant’s Big Secret
|
If the name Valeant Pharmaceuticals International doesn’t ring a bell, its business practices should. The Quebec-based drug manufacturer’s policy of implementing regular price increases that often run north of 100 percent has generated plenty of anger. Now a slim legal filing in California federal court is poised to make Valeant’s world rockier still.
Pharma
The Black World of Insys Therapeutics
|
Slowly but surely answers to the many riddles of how Insys Therapeutics could achieve its mercurial success are beginning to emerge.
Pharma
Insys Therapeutics and the New ‘Killing It’
|
On the evening of July 1, 2014, Carolyn “Suzy” Markland, a 58-year-old Jacksonville, Florida, resident with a degenerative disc disease, took her prescribed medicine — a 400-microgram dose of a Fentanyl spray called Subsys — and went straight to bed.